You are here:

Hikma Pharmaceuticals will receive up to $110m in debt financing from the International Finance Corporation, the World Bank’s private-sector lender, to improve access to generic medicine in the Middle East and North Africa.

IFC’s investment will enable Hikma to continue to provide skilled jobs and high-quality medicines to people in the region, many of whom lack access to the latest medical care, it said in a statement.

“Hikma and IFC have worked together for more than two decades to provide better healthcare for people in the region, and IFC’s latest investment in our company speaks to this long relationship built on our strong business,” said Hikma CEO Said Darwazah.